| | Presentation | Media | Date |
| AlzeCure's CEO Martin Jönsson at Redeye, April 11, 2024 (Swedish)
| |
|
April 11, 2024
|
| CEO Martin Jönsson presenting at Finwire, April 10, 2024 (Swedish)
| |
|
April 10, 2024
|
| AlzeCure's CEO Martin Jönsson at Redeye's event on Alzheimer's (Swedish)
| |
|
March 21, 2024
|
| AlzeCure presents new preclinical data with NeuroRestore ACD856 at leading Alzheimer’s conference, AD/PD 2024
|
|
|
March 7, 2024
|
| Expert Event - Advances in the treatment of Alzheimer’s disease – Small molecule Gamma-Secretase Modulators (GSMs) as promising disease-modifying treatments together
|
|
|
February 19, 2024
|
| Alzheimer’s disease and the amyloid hypothesis – Professor Henrik Zetterberg, MD, PhD, Gothenburg University & University College London, AlzeCure Pharma expert event
|
|
|
February 19, 2024
|
| Alzstatin: a small molecule disease modifying and preventive therapy against Alzheimer’s – Johan Sandin, PhD, CSO, AlzeCure; AlzeCure Pharma expert event with Johan Sandin, PhD, CSO, AlzeCure
|
|
|
February 19, 2024
|
| Welcome address, agenda & company overview, – Martin Jönsson, CEO, AlzeCure; AlzeCure Pharma expert event - Alzheimer’s around highly current gamma-secretase modulators
|
|
|
February 19, 2024
|
